Hepatitis

  • Most Topular Stories

  • Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification

    MedWorm: Hepatitis B
    21 Sep 2014 | 4:00 pm
    Conclusion: RB1 mutations can be used as a prognostic molecular biomarker for resectable hepatocellular carcinoma. Further study is required to investigate the potential role of FGF19 amplification in driving hepatocarcinogenesis in patients with liver cirrhosis and to investigate the potential of anti‐FGF19 treatment in these patients. (Hepatology 2014) (Source: Hepatology)MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.
  • Complications of Chronic Hepatitis C

    About.com Hepatitis: What's Hot Now
    hepatitis.guide@about.com
    22 Sep 2014 | 4:14 am
    Chronic hepatitis C affects the liver, but it's also associated with many extrahepatic diseases. Here's a list of some of them.
  • Lymph Nodes: Filter Stations for Lymph

    About.com Hepatitis: Most Popular Articles
    22 Sep 2014 | 5:43 am
    Lymph nodes contain large amounts of lymphocytes, a type of white blood cells that attack microbes. Page 7.
  • Similar, But Different – Hepatitis C Co-Infection and Superinfection

    Hepatitis Central
    Nicole Cutler L.Ac.
    16 Sep 2014 | 7:40 am
    Infecting an estimated 150 million people worldwide, the Hepatitis C virus has proven itself to be a tenacious foe. A leading cause of chronic liver disease, cirrhosis and liver cancer, there is not yet a vaccine to prevent Hepatitis C, and experts believe many are unknowingly infected. Once diagnosis has been made, treatment is arduous and may be ineffective for 10 to 50 percent who begin a cocktail of potent medications. Battling one strain of hepatitis is hard enough, but some people have more than one infection. As a blood borne virus, Hepatitis C is spread via blood-to-blood contact.
  • Sumitomo Chemical Announces Breakthrough in the Development of New Mode of Action Insecticide for Adult Mosquito Control

    Hepatitis News
    22 Sep 2014 | 7:44 am
    Development and recent submission to WHOPES of new mode of action insecticide product for adult mosquito control for application in IRS programs NEW YORK, NY, UNITED STATES, September 22, 2014 /EINPresswire.com/ -- Only 4 classes of insecticide are …
 
  • add this feed to my.Alltop

    About.com Hepatitis: What's Hot Now

  • Complications of Chronic Hepatitis C

    hepatitis.guide@about.com
    22 Sep 2014 | 4:14 am
    Chronic hepatitis C affects the liver, but it's also associated with many extrahepatic diseases. Here's a list of some of them.
  • Can I Catch Hepatitis A from Restaurant Food?

    hepatitis.guide@about.com
    22 Sep 2014 | 4:14 am
    Hepatitis A sometimes is spread by food handlers in restaurants. Does this mean that restaurants are dangerous places where people can be exposed to hepatitis A? Not really. Though this is a good time to talk about hand washing!
  • Can You Get Hepatitis C from Getting a Tattoo?

    hepatitis.guide@about.com
    22 Sep 2014 | 4:14 am
    Is there a link between hepatitis and tattoos? Yes, there is and here's how you can protect yourself.
  • Cirrhosis: What You Need To Know

    hepatitis.guide@about.com
    22 Sep 2014 | 4:14 am
    Cirrhosis of the Liver is extensive scarring, often caused by alcoholism or viral hepatitis, that starts to interfere with normal liver functions. Here are answers to five common questions about cirrhosis and links to more information.
  • What Is a Sustained Virologic Response or "SVR"?

    hepatitis.guide@about.com
    22 Sep 2014 | 4:14 am
    Sustained Virologic Response is the closest you'll get to a cure from hepatitis C. If you reach SVR, this means that you are virus free six months after treatment ends, and this is a good thing! Let's look at SVR a little more closely.
  • add this feed to my.Alltop

    About.com Hepatitis: Most Popular Articles

  • Lymph Nodes: Filter Stations for Lymph

    22 Sep 2014 | 5:43 am
    Lymph nodes contain large amounts of lymphocytes, a type of white blood cells that attack microbes. Page 7.
  • Fulminant

    22 Sep 2014 | 5:43 am
    Definition of Fulminant. Hepatitis.
  • Is There a Special Diet for Cirrhosis Patients?

    22 Sep 2014 | 5:43 am
    What is the best diet for cirrhosis? People with cirrhosis may need a special diet because of complications like ascites and hypoglycemia, but good advice is to eat a healthful diet of fruits, vegetables, whole grains and proteins of proper types and in appropriate amounts.
  • Are you on dialysis?

    22 Sep 2014 | 5:43 am
    Dialysis, also known as kidney dialysis or hemodialysis, is a medical procedure where a machine acts like a kidney and filters and cleans the blood. People who are on long-term dialysis (about 350,000 in the U.S.) have a significant chance of being hepatitis C positive (up to 15%). Page 5.
  • How Do I Know It's Hepatitis?

    22 Sep 2014 | 5:43 am
    The symptoms of hepatitis vary depending on what type of the disease a person has. It is also very hard to know if you have the disease without consulting a doctor.
 
  • add this feed to my.Alltop

    Hepatitis Central

  • Similar, But Different – Hepatitis C Co-Infection and Superinfection

    Nicole Cutler L.Ac.
    16 Sep 2014 | 7:40 am
    Infecting an estimated 150 million people worldwide, the Hepatitis C virus has proven itself to be a tenacious foe. A leading cause of chronic liver disease, cirrhosis and liver cancer, there is not yet a vaccine to prevent Hepatitis C, and experts believe many are unknowingly infected. Once diagnosis has been made, treatment is arduous and may be ineffective for 10 to 50 percent who begin a cocktail of potent medications. Battling one strain of hepatitis is hard enough, but some people have more than one infection. As a blood borne virus, Hepatitis C is spread via blood-to-blood contact.
  • Say it Ain’t So…New Hep C Drug to Surpass $84,000

    The Editors at Hepatitis Central
    15 Sep 2014 | 9:27 am
    Gilead to raise price for new hepatitis C drug above $84,000 By Deena Beasley September 12, 2014 (Reuters) – The next generation version of Gilead Sciences Inc’s $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive. Gregg Alton, Gilead’s executive vice president of corporate and medical affairs, declined to give an exact price for the new medicine, the first all-oral treatment for the virus which is expected to launch next month. Continue reading this entire article:…
  • How Quickly Can HCV be Eradicated?

    The Editors at Hepatitis Central
    11 Sep 2014 | 9:48 am
    Telaprevir Treatment Decays Hepatitis C Virus Faster in Blood than Liver By Catherine Kolonko | September 10, 2014 A recent study found that the hepatitis C virus decays during treatment with telaprevir faster in the bloodstream than it does in the liver, a discovery that could help pinpoint how long a patient needs to take medicine to rid the virus from the body. The study was conducted by Andrew Talal, MD, and other researchers at Weill Cornell Medical College in New York City and the findings published in Hepatology. It was the first time scientists traced in real time how the drug…
  • EU Approves Drug That Is Up to 100% Effective Against Hep C

    Nicole Cutler L.Ac.
    4 Sep 2014 | 12:55 pm
    Many Americans were prepping to celebrate Labor Day weekend while Europeans in the Hepatitis C community had something else to rejoice about. Instead of preparing for a barbeque or holiday sale, physicians, patients and researchers in Europe were ecstatic about the August 27, 2014 approval of daclatasivr, Bristol-Myers Squibb’s Hepatitis C virus NS5A inhibitor. Hepatitis C Overview Transmitted via blood-to-blood contact, Hepatitis C is a contagious, viral infection of the liver. Experts estimate that 150 million people are infected with chronic Hepatitis C worldwide, including about 3 to 4…
  • HCV Drug Update: Daklinza Gets Europe Approval

    The Editors at Hepatitis Central
    3 Sep 2014 | 6:45 am
    Bristol-Myers Hepatitis C Treatment Gets Europe Approval Daklinza Drug Combination Has Shown Strong Cure Rates, Company Says By Michael Calia August  27, 2014 European regulators have approved a Bristol-Myers Squibb Inc. BMY +0.22% drug for use in hepatitis C combination treatments, the company said Wednesday. The ruling by the European Commission allows for the drug, Daklinza, to be marketed in all of the European Union’s member states, Bristol said. Continue reading this entire article: http://online.wsj.com/articles/bristol-myers-hepatitis-c-treatment-gets-europe-approval-1409136824
  • add this feed to my.Alltop

    Hepatitis News

  • Sumitomo Chemical Announces Breakthrough in the Development of New Mode of Action Insecticide for Adult Mosquito Control

    22 Sep 2014 | 7:44 am
    Development and recent submission to WHOPES of new mode of action insecticide product for adult mosquito control for application in IRS programs NEW YORK, NY, UNITED STATES, September 22, 2014 /EINPresswire.com/ -- Only 4 classes of insecticide are …
  • SLU researcher to study new hepatitis C medication in children

    22 Sep 2014 | 7:30 am
    … drug treatment in adults with hepatitis C infection, a Saint Louis … current approach to treat the hepatitis C infection is with interferon … States are affected by the hepatitis C infection, out of which … ," Teckman said. Explore further: Hepatitis C cured in co-infected HIV …
  • Women at risk of Hepatitis B

    22 Sep 2014 | 1:56 am
    … , are more likely to contract Hepatitis B Gulu. A ten-year research … high prevalence rate of contracting Hepatitis B. The research, which began … ascertaining the prevalence rates of Hepatitis B in the region, especially … are currently suffering from Hepatitis B virus. Hepatitis B is a potentially …
  • CDC grant to study hepatitis C among drug users

    21 Sep 2014 | 8:46 pm
    … already have hepatitis C or are at risk of contracting hepatitis C … of hepatitis C.” The project is known as Southern Ohio Prevents Hepatitis … .Participants will be tested for hepatitis and HIV, and those who … area physicians for medical care. Hepatitis C is treatable and can …
  • New Hepatitis C Medication in Children to Be Studied

    21 Sep 2014 | 5:39 pm
    … drug treatment in adults with hepatitis C infection, a Saint Louis … current approach to treat the hepatitis C infection is with interferon … States are affected by the hepatitis C infection, out of which … 5 percent are children. "Hepatitis C takes a long time …
 
  • add this feed to my.Alltop

    Today

  • Paula Deen will return to TODAY for first time since tearful Matt Lauer interview

    Ian Sager
    22 Sep 2014 | 9:09 am
    Paula Deen will return to TODAY Tuesday for a live interview for the first time since her tearful conversation with Matt Lauer in June 2013.  The celebrity chef will discuss what she has learned, what has changed, as well as what's next for her following the scandal over racial slurs that impacted her life and career. Watch the video below to see Matt's interview from June 2013.
  • Jeffrey Tambor: 'Transparent' is most 'transformative role I've ever played'

    Ree Hines
    22 Sep 2014 | 9:07 am
    He's been a small-screen fixture for over 35 years, but despite Jeffrey Tambor's distinct roles in shows like "Hill Street Blues," "The Larry Sanders Show" and "Arrested Development," it's his role in the new Amazon series "Transparent" that he calls the "most transformative" of his career.
  • It's open enrollment! Here's three ways to save on health insurance

    Sharon Epperson
    22 Sep 2014 | 7:29 am
    It's open enrollment season, a short period of time when companies offer employees the opportunity to make changes to their health insurance and other benefits for the next year. In some cases, your choices this fall could potentially save you hundreds of dollars in 2015.But you have to take action right now.
  • TODAY studio gets 6 degrees of kissing Lenny Kravitz

    22 Sep 2014 | 7:14 am
    Lenny Kravitz woos our staff and anchors in TODAY’s Take when he kisses the hand of one of our producers, and the anchors follow suit so that they can be part of the Lenny-loving action. Tamron Hall, Willie Geist and Al Roker reflect on this and today’s top news headlines.
  • A tip of the hat: 'Blacklist' star James Spader reveals Red's fedora was his idea

    Randee Dawn
    22 Sep 2014 | 6:56 am
    Both hero and villain, Raymond "Red" Reddington from "The Blacklist" is one memorable character thanks in large part to the actor who plays him: James Spader. As it turns out, Spader deserves credit for something else that makes Red special. His ever-present chapeau.As Spader revealed in a TODAY interview Monday, Red's head-covering was his own idea.
  • add this feed to my.Alltop

    Hepatitis News

  • Dynavax Completes Enrollment of Phase 3 Study of HEPLISAV-B

    22 Sep 2014 | 9:46 am
    More than 8,250 adults, including over 1,100 diabetic subjects, have been enrolled at 40 sites in the U.S. This large safety and immunogenicity study is intended to provide an adequately-sized database of vaccinated subjects to enable the U.S. Food and Drug Administration to complete its review of the pending HEPLISAV-B Biologics License Application. The study is also designed to assess the immunogenicity of HEPLISAV-B in adults for whom approved hepatitis B vaccines are less effective, including those with type-2 diabetes mellitus.
  • Women at risk of Hepatitis B

    22 Sep 2014 | 5:59 am
    Gulu. A ten-year research carried out by staff of Gulu University in the department of Medicine has put expectant mothers in the region as having a high prevalence rate of contracting Hepatitis B. The research, which began in 2004, was aimed at ascertaining the prevalence rates of Hepatitis B in the region, especially among expectant mothers. The research was carried out at St Mary's Hospital, Lacor and Gulu Regional Referral Hospitals by Dr Pontius Bayo, Dr Caroline Oleo, Dr Emmanuel Ochola and Dr Amos Deogratius Mwaka.
  • Fibro-scan machine starts functioning at CHK : September 22, 2014,

    21 Sep 2014 | 10:43 pm
    KARACHI: Most modern equipment Fibro-scan machine has started functioning in first time in Sindh's largest public healthcare, Civil Hospital Karachi timely and correct diagnose of chronic liver disease has become easy for patients with liver disorders without any cost. Chief Medical Officer, Radiology Department, Civil Hospital Karachi, Dr Aijaz A Zubedi, said liver diseases like Hepatitis C & B were very common in the Sindh province and Fibro-scan is a unique machine which provides same information as with liver biopsy without any intervention.
  • Adam Summers: Rationing and the $1,000 pill

    21 Sep 2014 | 7:10 pm
    It is the $84,000 question. Gilead Sciences has developed a new hepatitis C drug called Sovaldi that vastly increases the cure rate and results in fewer side effects for patients.
  • Free Hep B screening for 1,200 people as part of liver disease awareness week

    21 Sep 2014 | 3:39 pm
    Free Hepatitis B screenings, which can help detect liver cancer, will be conducted for about 1,200 people next week. The tests, which are for those above 50 years old, will be done at public hospitals such as National University Hospital , Tan Tock Seng Hospital and Singapore General Hospital.
 
  • add this feed to my.Alltop

    HCV New Drug Research

  • ledipasvir/sofosbuvir - Gilead Signs generic licensing agreement for hepatitis C drug

    15 Sep 2014 | 11:16 am
    Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing CountriesDate(s): 15-Sep-2014 6:30 AM-- Indian companies granted license to produce generic sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir for treatment of chronic hepatitis C --NEW DELHI--(BUSINESS WIRE)--Sep. 15, 2014-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company has signed non-exclusive licensing agreements with seven India-based generic pharmaceutical manufacturers to expand access to its chronic hepatitis C…
  • HCV Newsletters - Update on Hepatitis C:Trials & Treatment and Protesting Gilead

    4 Sep 2014 | 8:04 am
    Update on Hepatitis C: Trials & Treatment and Protesting GileadHello everyone, here we are heading into September, where does the time go?During the next few weeks I will be busy working on a family project, the kids need nana to babysit, I can't wait! Once I get my short people under control the blog and website should get updated. On second thought, not sure that is likely to happen, if not, see you in a few weeks.... Last month the New York City Hepatitis C Task Force, along with Tracey Swan from the Treatment Action Group (TAG) offered a training seminar to help…
  • Why Is Everybody Picking on Sovaldi?

    3 Sep 2014 | 5:27 am
    Why Is Everybody Picking on Sovaldi?It is highly cost-effective at the $84,000 price, but....Lynn C. Klotz, Ph.DFor those infected with hepatitis C virus (HCV), the new drug Sovaldi seems like a godsend. As one part of a triple-drug therapy, it cures over 90% of infections in twelve weeks with few side effects for most HCV genotypes. Older HCV cures require many pills daily, have serious side effects, and cure only 75% of patients. But Sovaldi’s $84,000 price tag threatens to prevent widespread use...At Sovaldi’s present price, there is considerable resistance to diagnosing and treating…
  • Hepatitis C - Europe: More Direct-Acting Antivirals, More Controversy

    2 Sep 2014 | 5:44 am
    Europe: More Direct-Acting Antivirals, More ControversyBy Guest Blogger | Published: September 2, 2014SourceThe storms raging across Europe—and beyond—over the pricing of new hepatitis C treatments have been intensified by the European Union’s approval last week of the latest directly-acting antiviral, Bristol-Myers Squibb’s Daklinza (daclatasvir). Just two months after the European Medicines Agency gave a positive opinion on the drug, the formal authorization was delivered for use in combination for the treatment of chronic infection in adults.The company will now start negotiations…
  • Weekend Reading: Evolution of Hepatitis C Virus Treatment

    31 Aug 2014 | 7:05 am
    Evolution of Hepatitis C Virus TreatmentGood afternoon folks, welcome to this edition of weekend reading, we close out the month with a podcast from the August issue of Gastroenterology & Hepatology. Dr. Kuemmerle along with Dr. Fasiha Kanwal discuss SVR rates using first generation DAA therapies, current agents, and what we can expect in the future. In addition, access to treatment is examined with an emphasis on making HCV treatment more affordable to everyone.Evolution of Hepatitis C Virus TreatmentAn editorial in the August issue of CGH discusses…
 
Log in